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Abstract 
 
Objective: To determine the range and heterogeneity of outcomes reported in randomized 
controlled trials (RCTs) of interventions for children with chronic kidney disease (CKD).  
 
Study Design: The Cochrane Kidney and Transplant Specialized Register was searched to March 
2016. Randomized trials involving children across all stages of CKD were selected. All outcome 
domains and measurements were extracted from included trials. The frequency and characteristics 
of the outcome domains and measures were evaluated. 
 
Results: From 205 trials included, 6158 different measurements of 100 different outcome 
domains were reported, with a median of 22 domains per trial (interquartile range [IQR] 13 to 41). 
Overall, 52 domains (52%) were surrogate, 38 (38%) were clinical, and 10 (10%) were patient-
reported. The five most commonly reported domains were blood pressure (76 [37%] trials), 
relapse/remission (70 [34%]), kidney function (66 [32%]), infection (61 [30%]), and 
height/pubertal development (51 [25%]). Mortality (14%), cardiovascular disease (4%) and 
quality of life (QOL) (1%) were reported infrequently. The two most frequently reported 
outcomes, blood pressure and relapse/remission, had 56 and 81 different outcome measures, 
respectively. 
 
Conclusions: The outcomes reported in clinical trials involving children with CKD are extremely 
heterogeneous and are most often surrogate outcomes, rather than clinical and patient-centered 
outcomes such as cardiovascular disease and QOL. Efforts to ensure consistent reporting of 
outcomes that are important to patients and clinicians will improve the value of trials to guide 
clinical decision-making. In our study, non-English articles were excluded.  
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Introduction 
 
Since the recognition of children as “therapeutic orphans” in the 1960s,(1) there has been a wave 
of international efforts to improve trial-based evidence to support the use of health interventions 
in the pediatric setting.(1-12) The past two decades has seen an increase in the number of trials 
conducted in children since the United States and Europe revised legislation on labelling of 
medicines to mandate pediatric data.
3
 Also, major pediatric trial networks have been established 
globally, including the US National Institute of Child Health and Human Development Pediatric 
Trial Network and the Network of Pediatric Research at the European Medicines Agency, to 
improve infrastructure and capacity for pediatric trials.(13, 14) 
 
Despite this upsurge in pediatric clinical trials, the relevance and value of trials may be limited by 
problems in the prioritization, design, reporting and dissemination of research, including 
outcomes measured and reported.(15-21) Trials are only as informative as their outcomes,(22) yet 
many report outcomes that may not be directly relevant to patients and clinicians, and do not 
involve children and caregivers in the selection of outcomes.(23-25) Analyses of pediatric trials 
within specific health conditions have shown that the outcomes reported are extremely variable, 
including the definitions and measures used(23-27), which limits comparability of the 
effectiveness of interventions across studies.(16) Initiatives to establish core outcomes, to be 
reported at a minimum in all trials with specific health condition, such as The Outcome Measures 
in Rheumatology (OMERACT), have demonstrated improvement in the relevance and reporting 
of outcomes in trials,(22, 23, 28-30) though core outcome sets are generally lacking in the 
pediatric setting. 
 
Children with chronic kidney disease (CKD) have a mortality rate up to 30-times higher than the 
age-matched general population, and those who progress to end-stage kidney disease depend on 
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dialysis or a kidney transplant for survival.(31, 32) Although many trials have been conducted in 
children with CKD, the risk and prevalence of comorbid conditions, treatment complications, 
developmental problems, debilitating symptoms, such as fatigue, and impaired quality of life 
(QOL) remain high.(33-44) Improvements in health care and outcomes through research rely on 
the relevance and consistency of outcomes reported in trials in this vulnerable population. 
Affected children depend on their caregivers and clinicians to provide long-term, complex, and 
highly technical treatments that have profound implications for their development and well-being. 
We aimed to describe the scope and consistency of outcome domains and measures in trials 
involving children with all stage of CKD, to inform strategies for establishing core outcomes that 
are important to children, families and clinicians to be reported in trials, to inform clinical 
decision making and ultimately to improve the outcomes for children with CKD. 
 
Methods 
 
Selection criteria 
 
We searched the Cochrane Kidney and Transplant Specialized Register for all randomized 
controlled trials (RCT) involving children aged up to 21 years or less (the upper age limit to 
define the pediatric population is up to 21 years in the United States(45)) with any CKD diagnosis 
and at treatment stage (CKD Stage 1-5 [not on renal replacement therapy], 5D [hemodialysis or 
peritoneal dialysis] and 5T [kidney transplant]) up to March 2016 (Figure 1 (online)). We used 
search terms relating to children and pediatrics. Trials that included more than 50% of patients 
aged above 21 years were excluded. Trials that included children with chronic conditions, but did 
not report data from the CKD population, were not eligible.  
 
Data extraction 
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We extracted the following trial characteristics from each trial: publication year, setting 
(participating countries), sample size, mean age of participants, study duration, intervention type, 
and all outcomes. We defined outcome measures as any measures reported separately for all trial 
arms. We extracted all specifications of the outcome measures, if reported, including the: outcome 
domain (e.g. blood pressure), specific measurement (e.g. percentage of hypertensive patients), 
method of aggregation (e.g. percentage change), specific metric (between commencement and end 
of the trial), and time point of measurement (defined as the time frame from trial commencement 
to when the outcome was measured).(46)   
 
Analysis 
 
We categorized all the outcome measures from all the included trials into outcome domains. The 
first author (LC) drafted the initial list of outcome domains. This was cross-checked by four 
reviewers and revised until consensus was achieved (AT, BS, GR, JCC). The outcome measures 
were then grouped according to the final list of outcome domains, which was re-reviewed by the 
same four reviewers. All outcome domains were further categorized as surrogate (biochemical or 
physiological outcomes i.e. pathophysiological manifestations of health conditions, including 
such as blood pressure(47)), clinical (medical outcome of a condition or treatment), and patient-
reported (outcomes reported on by patients and caregivers, typically related to how the patients 
function or feel in relations to a health condition or therapy), based on standard 
nomenclature.(48)
,
(49) Some outcome domains included measures that straddled several 
categories – surrogate, clinical and patient-reported. Thus, classification of the domains was based 
on the largest proportion of outcome measures. The number of trials, and dialysis- and 
transplantation-specific trials that reported each outcome domain were calculated. 
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We conducted a detailed analysis of outcome measures of the three outcome domains in each 
category that were reported most frequently across trials, as well as the three pediatric-specific 
domains (height and pubertal development, weight/BMI/body composition and school 
performance). The measurement, aggregation, metric and timing as reported in the primary 
studies were analyzed. We retained the original term if studies did not further define or provide 
details on the outcome measure. Statistical analyses of frequency were conducted using R version 
3.2.3 (R Foundation for Statistical Computing, Vienna, Austria, URL http://www.R-project.org/). 
 
Results 
 
Characteristics of trials 
 
Our search yielded 1266 trials, of which 205 included 2174 children with CKD (Table 1). The 
trial characteristics are shown in Table 1. Overall about half of trials involved children with CKD 
Stage 1 to 5 (123 [52.1%] trials), 32 [13.6%]) trials involved patients on hemodialysis, 40 [16.9%] 
involved peritoneal dialysis, and 41 (17.4%) involved kidney transplant recipients. The setting of 
the trials spanned 43 countries, including the United States (51 [25%] trials), India (18 [9%]), 
Japan (15 [7%]), Germany (14 [7%]), and England (14 [7%]); and 28 (14%) trials were 
multinational. The trials were published from 1970 to 2015. The median trial duration was 12 
months (interquartile range [IQR] 6 to 24 months), and the median sample size was 40 patients 
(IQR 22 to 76 patients), with only six (2.9%) larger than 200.  
 
Outcome measures and outcome domains 
 
Across 205 trials, 6158 outcome measures were reported. The number of outcome measures per 
trial (including time points of measurement) ranged from 1 to 145, with a median of 22 per trial 
(IQR 13 to 41). The number of unique outcome measures per trial (excluding time points) ranged 
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from 1 to 64, with a median of 15 (IQR 9 to 26). We excluded 382 outcome measures because 
they were not a direct health outcome measured in patients (e.g. “mean cold ischemia time,” and 
“medication dose/use/duration”) or were specific to a single intervention within a trial (e.g. 
“number of patients monitored and educated”). The remaining 5776 were classified into 100 
outcome domains and these were grouped into: surrogate (52 [52%]), clinical (38 [38%]) and 
patient-reported outcomes (10 [10%]) (Table 2, 3, 4; online). Nine outcome domains were 
specific to transplantation, and four were specific to dialysis.  
 
Frequency of outcome domains reported in trials 
 
Figure 2 depicts the proportion of trials that reported each outcome domain. The six most 
commonly reported outcome domains were: blood pressure (76 [37.1%] trials), relapse/ remission 
(70 [34.1%]), kidney function (66 [32.2%]), infection (61 [29.8%], height/pubertal development 
(51 [24.9%]) and weight/body mass index/body composition (50 [24.4%]). Mortality and 
cardiovascular disease were reported in 28 (13.7%) and 8 (3.9%) of trials, respectively. 
Depression and QoL (global) were reported in 2 (1.0%) of trials, and school performance was 
reported in 1 (0.5%) of trial. Table 5 details the proportion of trials that reported the 10 most 
frequent outcome domains, and the proportion of trials reporting each outcome domain.  
 
The number of trials that reported a minimum of one surrogate outcome domain was 180 (87.8%), 
and 164 (80.0%) and 49 (23.9%) reported at least one clinical and one patient-reported domain, 
respectively. From the 30 (30%) outcomes reported by at least 10% of trials, 17 were surrogate, 
12 were clinical and one was patient-reported.  
 
Outcome measures and time points 
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Figure 3 shows the number of outcome measures and time points of measurement for 10 outcome 
domains (the three most frequently reported surrogate and clinical outcome domains, two most 
frequently reported patient-reported domains, and two pediatric-specific domains). The outcome 
measures and time points of measurement for each outcome domain listed in Figure 3, excluding 
“school performance” are shown in Figure 4a-i; online.  
 
The three most frequently reported surrogate outcomes were “blood pressure” (56 outcome 
measures [168 including different time points]; Figure 4b; online), “relapse/remission (82 [240 
including time points]; Figure 4c; online) and “kidney function” (47 outcome measures [173 
including time points]; Figure 4a; online). The clinical outcomes of “infection”, “height and 
pubertal development” and “dermatologic disorder” had 114 (165 including time points), 34 (137 
including time points) and 24 (52 including time points) different outcome measures, respectively 
(Figure 4d-f; online). For patient-reported outcomes, “pain” (Figure 4g; online) and 
“psychological impact” (Figure 4h; online) had 27 (50 including time points) and 10 (15 including 
time points) measures, respectively. There were two pediatric-specific outcomes, “weight/body 
mass index/body composition” and “school performance”. The former had 40 (114 including time 
points) (Figure 4i; online), and the latter had only one outcome measure, at one time point.  
 
Characteristics of primary outcomes 
 
Across the 205 trials, 109 (53.2%) did not specify the primary outcome, 68 (33.2%) specified 
several outcomes as primary outcomes, and 28 (13.6%) specified one unique primary outcome. 
The outcomes specified as primary outcomes corresponded to 36 different outcome domains: 24 
(66.7%) were surrogate outcomes, 10 (27.8%) were clinical outcomes and 2 (5.6%) were patient 
reported outcomes. The 6 most frequently reported primary outcomes were “relapse/ remission” 
(43 [44.8%] trials), “proteinuria, albuminuria” (22 [22.9%] trials), “kidney function” (18 [18.8%] 
trials), “height and pubertal development” (15 [15.6%] trials), “anemia/hemoglobin/iron” (9 
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[9.4%] trials) and bone density/markers” (6 [6.3%] trials). Table 6; online details the primary 
outcome domains, and the proportion of trials reporting each one. 
 
Discussion 
 
Biochemical surrogate outcomes comprised over half of the outcome domains reported in clinical 
trials involving children with CKD with blood pressure, kidney function, weight and urine protein 
being the most frequently reported. These were much more common compared with clinical and 
patient-centered outcomes such as mortality (14%), cardiovascular disease (4%), and QOL (1% of 
trials). In terms of pediatric-specific outcomes, physical development (height and pubertal 
development, weight/BMI/body composition) were reported in more than 25% of trials, but 
school performance was assessed in only one trial. Thus, the relevance of current trials to guide 
treatment decisions based on outcomes that are important to children with CKD and their 
caregivers may be disputable. Also, there is wide heterogeneity of outcome domains reported 
across trials and, within each outcome domain, large variability in the definitions, time points, and 
measures used. Such inconsistencies in outcome reporting obscure assessments about the 
comparative effectiveness of interventions across trials. 
 
Surrogate outcomes, such as serum biomarkers, are frequently used in trials because they require 
a smaller sample size, shorter time-frame, and fewer resources to evaluate treatment effectiveness. 
These may be key considerations given the relatively small population of children with CKD, and 
the additional ethical and logistical requirements to conduct trials in children. However, surrogate 
outcomes have not been robustly validated in this setting and do not bear direct relevance to 
patients and their families. Serum phosphate, serum calcium, parathyroid hormone and 
anemia/hemoglobin/iron were reported in more than 15% of trials but there is no evidence to 
indicate that they predict mortality and cardiovascular events in patients with CKD.(49-55) While 
some physiological markers may be appropriate measures of short-term disease activity for acute 
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conditions,(56) they are arguably less informative in chronic conditions.  Further studies are 
needed to validate surrogate outcomes such as parathyroid hormone, serum phosphate and serum 
calcium. 
 
Many outcomes that have been identified as important and clinically relevant to children with 
CKD were absent in most trials. Studies that have directly elicited perspectives from children 
living with CKD have identified their priorities as school attendance and performance, anxiety, 
social participation, ability to participate in physical activity, hospitalization, and fatigue.(42, 56-
61) However, patient-reported outcomes constituted only 10% of all outcome domains reported, 
and were infrequently reported. Psychological problems, including depression, were reported in 
less than 10% of trials. School performance, fatigue, physical function and QOL were reported in 
just 1% of trials. No trials reported on social participation. The omission of outcomes important to 
children with CKD can hamper efforts to implement interventions and strategies to optimize 
outcomes that are meaningful to patients themselves. Further work is needed to identify 
dimensions of QOL that are important to patients and subsequently develop feasible and validated 
measures to use in trials. 
 
There was also a paucity of outcomes identified as important to parents, who have a central role in 
monitoring and managing the health and treatment of their child with CKD. Physical, cognitive, 
and social-emotional development have been identified as a major parental concern.(56, 61) 
Linear growth (height and pubertal development and weight/BMI/body composition) were both 
reported in more than 25% of trials. However, no trials reported on neurocognitive development. 
Furthermore, parents share their children’s concerns regarding school performance, social 
participation and mortality, all of which were underreported.(56, 61)  We acknowledge that 
mortality rates are low in the pediatric population. However, the omission of outcomes that are of 
explicit importance to children and parents can diminish the relevance of trials. 
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Some outcomes were specific to certain stages of treatment. For example, graft function, graft 
loss, chronic graft rejection, graft histology/pathology, malignancy were specific to 
transplantation, while dialysis adequacy and vascular access complications were specific to 
dialysis. Many outcomes identified as clinically relevant to children undergoing dialysis or with a 
kidney transplant were also absent in most trials. In the 55 dialysis-specific trials, four of the five 
most commonly reported outcomes were surrogate markers (phosphate (21 [38.2%] dialysis 
specific trials), parathyroid hormone (18 [32.7%]), calcium (18 [32.7%]), bone density/markers 
(17 [31.0%]), and one was clinical (infection (17 [31.0%]). However, the primary concerns of 
children undergoing dialysis have been identified to be related to social participation, fatigue, 
school performance and exercise capacity and height.(60) Height/pubertal development was 
reported in only 7 (16%) dialysis-specific trials, and school performance and exercise capacity 
were reported in only one. Social participation and fatigue were not reported at all in dialysis-
specific trials. 
 
Among the 41 transplant-specific trials, the five most commonly reported outcomes were all 
surrogate outcomes: graft function (30 [73.2%] transplant-specific trials), acute graft rejection (20 
[48.8%]), graft loss (19 [46.3%]), height and pubertal development (18 [44.0%]) and blood 
pressure (17 [41.5%]). Graft survival and physical side effects (e.g. changes in appearance) have 
been identified by pediatric kidney transplant recipients as important.(62) However, mortality was 
reported in only 14 [38%] transplant-specific studies, and physical side-effects and symptoms 
including weight gain (11 [30%]), pain (4 [10.8%]), and hyperhydrosis (1 [0.5%]) were rarely 
reported. 
 
We have also demonstrated substantial multiplicity and inconsistency in outcome domains and 
measures across trials in children with CKD, with 6158 outcome measures and time points 
reported across the 100 outcome domains. Blood pressure (the most frequently reported outcome) 
was measured in 37% of trials, however had 56 different outcome measures. Without consistency 
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in the way outcomes are measured and reported, it is difficult to assess the relative effect of 
interventions across studies.(63) Furthermore, the majority of trials had a duration less than 24 
months (63.4%) and a small sample size of 1-50 patients (62%), leading to considerable 
imprecision regarding treatment effects and uncertainty on the long-term impact of any treatment 
decisions. 
 
A number of other studies have systematically evaluated the reporting of outcome domains in 
trials of pediatric conditions such as asthma,(56) autism,(64) appendicitis,(65) acute diarrheal 
illness,(26) neurodisability,(66) cerebral palsy(67) and otitis media.(68) These reviews have 
identified similar problems in outcome reporting. There is a dominance of clinical and 
physiological markers of short-term disease activity, and in contrast limited focus of QOL, 
functional status and long-term outcomes. Previous studies have also demonstrated a marked 
inconsistency across trials in the way that outcomes are measured and reported, non-uniformity in 
the definitions of clinical events used as endpoints, a lack of clarity in reporting methods, and 
problems with reporting bias.(24-26, 56, 64, 65) 
 
 
This work provides a comprehensive and detailed analysis of the range and consistency of 
outcome domains and measures reported in trials in children across all stages of CKD. However, 
this review has some potential limitations. We used Cochrane reviews as a sampling frame as it 
was not feasible to include all trials, however the reviews cover the topics of importance in the 
field. We did not appraise the risk of bias in the included trials given our focus on the reporting of 
outcomes – not the results. Non-English trials were excluded and most studies were conducted in 
high-income countries. 
 
Our findings emphasize the importance of developing a minimum set of core outcomes to be 
measured and reported in RCTs. Core outcome sets increase the likelihood that important 
outcomes will be measured, improve evidence synthesis by reducing heterogeneity between 
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studies, and reduce outcome reporting bias.(56) Core outcome sets have been developed for other 
medical conditions and the Core Outcome Measures in Effectiveness Trials (COMET) 
database(69) contains over 120 studies on the development of core outcome sets. However, 
studies in the pediatric setting are scarce although work has been done in the areas of otitis 
media,(61, 68) asthma,(56) neurodisability,(66) autism,(64) and cerebral palsy.(67) No core 
outcome set exists in pediatric CKD. 
 
The Standardized Outcomes in Nephrology (SONG) Initiative, which commenced in 2014, aims 
to established a core outcome set across the spectrum of CKD that is based on the shared priorities 
of all stakeholders.(70) SONG-Kids is now underway, engaging children, parents and health 
professionals in a process to develop a core outcome set for trials in children and adolescents 
across all stages of CKD.(71) 
 
There is a clear dominance of surrogate outcomes reported in trials in children with CKD, whilst 
outcomes that have direct relevance for children, their parents and clinicians are relatively rare. 
Furthermore, the heterogeneity and inconsistency in the way outcomes are defined, assessed and 
measured also limits ability to synthesize results across studies, including those assessing similar 
interventions. This reiterates an urgent need to improve the relevance and reliability of trials in 
decision making through the development of a core outcomes set to be reported as a minimum in 
trials in children with CKD. A core outcome set can be expected to improve outcome reporting in 
trials and subsequently lead to enhanced QOL, treatment satisfaction, and health outcomes of 
children and adolescents with CKD.    
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Figure legends 
 
Figure 1; online. Search results 
 
Figure 2. Number of trials reporting each outcome domain (total 205 trials, 100 outcome 
domains) 
 
Figure 3. Number of outcomes measures (definitions and time points) for the most frequently 
reported and pediatric-specific outcome domains among trials  
 
Figure 4a; online. Frequency of outcomes measures (definitions and time points) among trials 
reporting blood pressure (76 trials, 56 outcomes measures) 
 
Figure 4b; online. Frequency of outcomes measures (definitions and time points) among trials 
reporting relapse/remission (67 trials, 82 outcomes measures) 
 
Figure 4c; online. Frequency of outcomes measures (definitions and time points) among trials 
reporting kidney function (66 trials, 47 outcomes measures) 
 
Figure 4d; online. Frequency of outcomes measures (definitions and time points) among trials 
reporting infection (61 trials, 114 outcomes measures) 
 
Figure 4e; online. Frequency of outcomes measures (definitions and time points) among trials 
reporting height and pubertal development (52 trials, 34 outcomes measures 
 
Figure 4f; online. Frequency of outcomes measures (definitions and time points) among trials 
reporting dermatologic disorder (46 trials, 24 outcomes measures) 
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Figure 4g; online. Frequency of outcomes measures (definitions and time points) among trials 
reporting pain (34 trials, 27 outcomes measures) 
 
Figure 4h; online. Frequency of outcomes measures (definitions and time points) among trials 
reporting psychological impact (15 trials, 10 outcomes measures) 
 
Figure 4i; online. Frequency of outcomes measures (definitions and time points) among trials 
reporting weight/BMI/body composition (50 trials, 40 outcomes measures) 
 
 
 
 
Table 1. Characteristics of included trials (n=205) 
Trial characteristic Number of trials (%) 
Year of publication  
<1980 13 (6.3) 
1980-1989 18 (8.8) 
1990-1999 54 (26.3) 
2000-2009 77 (37.6) 
≥2010 43 (21.0) 
Duration of trial (months)  
< 3 24(11.7) 
3 – 5  26(12.7) 
6 – 11  32 (15.6) 
12 – 23  48(23.4) 
≥ 24 75(36.6) 
Sample size (n)  
1 to 50 127 (62.0) 
51 to 100 39 (19.0) 
101 to 150 19 (9.3) 
151 to 200 11 (5.3) 
>200 6 (2.9) 
Unspecified  3 (1.5) 
Location  
America  66 (32.2) 
Europe 53 (25.9) 
Asia 51 (24.9) 
Africa 6 (2.9) 
Oceania 1 (0.5) 
Multinational studies 28 (13.7) 
CKD stage *   
Table 1
1 to 5  123 (52.1) 
Hemodialysis  32 (13.6) 
Peritoneal dialysis 40 (16.9) 
Kidney transplantation 41 (17.4) 
Primary kidney disease   
Nephrotic syndrome  31 (10.3) 
Congenital abnormalities of the kidney and urinary tract (CAKUT) 25 (8.3) 
Focal segmental glomerulosclerosis (FSGS) 24 (8.0) 
Obstructive uropathy 14 (4.7) 
Hemolytic uraemic syndrome (HUS) 13 (4.3) 
Glomerulonephritis  12 (4.0) 
Other 121 (40.2) 
Non-specified 61 (20.3) 
Intervention type  
Immunomodulation  100 (48.8) 
Bone health 40 (19.5) 
Dietary/nutritional 15 (7.3) 
Hematological 11 (6.0) 
Anti-hypertensive agent 8 (3.9) 
Lipid lowering agents 7 (3.4) 
Dialysis-specific 6 (2.9) 
Anti-infective agents 5 (2.4) 
Diuretics 1 (0.5) 
Other 12 (5.9) 
* Multiple categories possible 
 
 
Table 2; online only. Proportion of trials reporting each surrogate outcome (205 trials, 51 outcome 
domains) 
 
Domains 
(surrogate outcomes) 
 Number of trials  
All n=205 (%) Dialysis n=55 (%) Transplantation n=41 (%) 
Blood pressure 76 (37.1) 14 (25.5) 17 (41.5) 
Relapse/remission 70 (34.1) 1 (1.8) 1 (2.4) 
Kidney function 66 (32.2) 5 (9.1) 3 (7.3) 
Weight/BMI/body composition 50 (24.4) 7 (12.7) 12 (29.3) 
Proteinuria, albuminuria 49 (23.9) 2 (3.6) 3 (7.3) 
Blood protein, albumin 48 (23.4) 9 (16.4) 3 (7.3) 
Lipids 47 (22.9) 6 (10.9) 16 (39.0) 
Anemia/haemoglobin/iron 44 (21.5) 15 (27.3) 8 (20.0) 
Phosphate 39 (19.0) 21 (38.2) 7 (17.1) 
White blood cells 39 (19.0) 1 (1.8) 8 (19.5) 
Bone density/markers 37 (18.0) 17 (30.9) 7 (17.1) 
Calcium 34 (16.6) 18 (32.7) 6 (14.6) 
Urea 31 (15.1) 8 (14.5) 4 (9.8) 
Glucose metabolism 31 (15.1) 9 (16.4) 16 (39.0) 
Parathyroid hormone 31 (15.1) 18 (32.7) 6 (14.6) 
Graft function 30 (14.6)  30 (73.2) 
Electrolytes (other) 25 (12.2) 5 (9.1) 8 (19.5) 
Liver function 24 (11.7) 3 (5.5) 4 (9.8) 
Potassium 22 (10.7) 6 (10.9) 4 (9.8) 
Acute graft rejection 20 (9.8) 2 (3.6) 20 (48.8) 
Inflammatory markers/oxidative stress 19 (9.3) 6 (10.9) 6 (14.6) 
Acid-base balance 25 (12.2) 11 (20.0) 4 (9.8) 
Vitamin D 15 (7.3) 9 (16.4) 2 (4.9) 
Dialysis adequacy 13 (6.3) 13 (23.6) - 
Platelets, coagulation 14 (6.8) 3 (5.5) 2 (4.9) 
Kidney disease progression/change 12 (5.9) 1 (1.8) 1 (2.4) 
Graft rejection (unspecified) 11 (5.4) - 11 (26.8) 
Table 2; online only
Growth hormone 11 (5.4) 5 (9.1) 5 (12.2) 
Respiratory function 11 (5.4) 3 (5.5) 4 (9.8) 
Acute kidney injury 9 (4.4) - 1 (2.4) 
Serum immunoglobulins 9 (4.4) 1 (1.8) 1 (2.4) 
Calcium x Phosphate 9 (4.4) 6 (10.9) - 
Graft histology/ pathology (excl. rejection) 8 (3.9) - 8 (19.5) 
Uric acid 8 (3.9) 1 (1.8) - 
Caloric intake 8 (3.9) 4 (7.3) - 
Protein intake 7 (3.4) 3 (5.5) - 
Electrolyte intake 7 (3.4) 5 (9.1) - 
Renal tubular dysfunction  6 (2.9) 3 (5.5) - 
Fertility 5 (2.4) 2 (3.6) - 
Cardiac function 5 (2.4) 1 (1.8) - 
Rhabdomyolysis 5 (2.4) 1 (1.8) 2 (4.9) 
Endocrine function 4 (2.0) 1 (1.8) 1 (2.4) 
Nitrates 3 (1.5) 1 (1.8) 1 (2.4) 
Thyroid function 3 (1.5) 1 (1.8) 1 (2.4) 
Amino acids  3 (1.5) 2 (3.6) - 
Aluminium toxicity 2 (1.0) 1 (1.8) - 
Urine volume 2 (1.0) 1 (1.8) - 
Blood pressure regulating hormone 2 (1.0) - - 
Carnitine 2 (1.0) 2 (3.6) - 
Chronic graft rejection 2 (1.0) - 2 (4.9) 
Vitamin E 1 (0.5) - - 
Donor-specific anti-HLA antibody 1 (0.5) - 1 (2.4) 
 
-, no trials reported 
Table 3; online only. Proportion of trials reporting each clinical outcome (205 trials, 38 outcome domains) 
 
Domains                       
(clinical outcomes) 
 Number of trials  
All n=205 (%) Dialysis n=55 (%) Transplantation n=41 (%) 
Infection 61 (29.8) 17 (30.9) 16 (39.0) 
Height and pubertal development 51 (24.9) 12 (21.8) 18 (43.9) 
Dermatologic disorder 46 (22.4) 5 (9.1) 4 (9.8) 
    
Gastrointestinal effects 43 (21.0) 7 (12.7) 8 (19.5) 
Adverse events (non-specified) 36 (17.6) 6 (10.9) 10 (24.4) 
Mortality 28 (13.7) 3 (5.5) 15 (36.6) 
Neurologic disorders 26 (12.7) 3 (5.5) 6 (14.6) 
Urologic complication 23 (11.2) 2 (3.6) 6 (14.6) 
Respiratory disease 22 (10.7) 4 (7.3) 6 (14.6) 
Graft loss 19 (9.3) - 19 (46.3) 
Vision disorder 18 (8.8) 2 (3.6) 1 (2.4) 
Mouth and gum disorders 14 (6.8) - 3 (7.3) 
Bone disease/fractures 14 (6.8) 4 (7.3) 5 (12.2) 
Cushing syndrome 14 (6.8) - 1 (2.4) 
Cardiovascular disease 8 (3.9) 4 (7.3) 1 (2.4) 
Dialysis treatment complications 8 (3.9) 7 (12.7) 2 (4.9) 
Malignancy – PTLD 8 (3.9) - 8 (19.5) 
Malignancy (unspecified) 6 (2.9) 1 (1.8) 3 (7.3) 
Edema 6 (2.9) 2 (3.6)  - 
Hospitalization 6 (2.9) 1 (1.8) 4 (9.8) 
Procedural complication 5 (2.4) - 1 (2.4) 
Allergic reaction 5 (2.4) 3 (5.5) - 
Bleeding/hematoma 5 (2.4) 1 (1.8) 1 (24) 
Muscular complications  5 (2.4) 1 (1.8) 3 (7.3) 
Requirement of transplantation 4 (2.0) 2 (3.6) - 
Fever/chills 4 (2.0) 2 (3.6) 2 (4.9) 
Compliance 4 (2.0) 3 (5.5) 1 (2.4) 
Table 3; online only
Time on dialysis 3 (1.5) 1 (1.8) 2 (4.9) 
Metabolic and nutritional disorders 3 (1.5) - 1 (2.4) 
End stage kidney disease  3 (1.5) - - 
Dehydration 2 (1.0) - 2 (4.9) 
Arthritis and joint pain 2 (1.0) - - 
Hearing impairment 2 (1.0) 1 (1.8) - 
Physical injury 2 (1.0) 1 (1.8) - 
Vascular access complications 1 (0.5) 1 (1.8) - 
Malignancy - skin 1 (0.5) - 1 (2.4) 
Pulmonary embolus 1 (0.5) - - 
Hyperhidrosis 1 (0.5) - - 
 
 
 
Table 4; online only. Proportion of trials reporting each patient-reported outcome (205 trials, 10 outcome 
domains) 
 
Domains                        
(patient-reported outcomes) 
 Number of trials  
Total trials, n=205 (%) Dialysis trials, n=55 (%) 
Transplantation trials, 
n=41 (%) 
Pain 33 (16.1) 12 (21.8) 5 (12.2) 
Psychological impact 15 (7.3) 1 (1.8) - 
Treatment satisfaction 2 (1.0) 1 (1.8) 1 (2.4) 
Sleep disorder 2 (1.0) 1 (1.8) - 
Fatigue 2 (1.0) - - 
Quality of life (global) 2 (1.0) 1 (1.8) - 
Depression 2 (1.0) 1 (1.8) - 
Food enjoyment/appetite 2 (1.0) 1 (1.8) - 
School performance 1 (0.5) 1 (1.8) - 
Physical function/mobility/ disability 1 (0.5) 1 (1.8) - 
 
 
 
 
Table 4; online only
Table 5. Proportion of trials reporting the top 10 most frequently reported outcome domains 
 
Domains 
(all outcomes) 
 Number of trials  
All n=205 (%) Dialysis n=55 (%) Transplantation n=41 (%) 
Blood pressure 76 (37.1) 14 (25.5) 17 (41.5) 
Relapse/remission 70 (34.1) 1 (1.8) 1 (2.4) 
Kidney function 66 (32.2) 5 (9.1) 3 (7.3) 
Infection 61 (29.8) 17 (30.9) 16 (39.0) 
Height and pubertal development 51 (24.9) 12 (21.8) 18 (43.9) 
Weight/BMI/body composition 50 (24.4) 7 (12.7) 12 (29.3) 
Proteinuria, albuminuria 49 (23.9) 2 (3.6) 3 (7.3) 
Blood protein, albumin 48 (23.4) 9 (16.4) 3 (7.3) 
Lipids 47 (22.9) 6 (10.9) 16 (39.0) 
Dermatologic disorder 46 (22.4) 5 (9.1) 4 (9.8) 
 
 
Table 5
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Table 6; online only. Primary outcomes reported in trials conducted in children with CKD 
 
Domains of primary outcomes (96 trials*) Number of trials (%) 
Relapse/remission 43 (44.8) 
Proteinuria, albuminuria 22 (22.9) 
Kidney function 18 (18.8) 
Height and pubertal development 15 (15.6) 
Anemia/haemoglobin/iron 9 (9.4) 
Bone density/markers 6 (6.3) 
Acute graft rejection 5 (5.2)  
Adverse events  5 (5.2) 
Glucose metabolism 5 (5.2) 
Infection 5 (5.2) 
Lipids  5 (5.2) 
Parathyroid hormone 4 (4.2) 
Pain 3 (3.1) 
Kidney disease progression/change 3 (3.1) 
Dialysis adequacy 3 (3.1) 
Cardiac function 2 (2.1) 
Cushing’s syndrome  2 (2.1) 
Urologic complication 2 (2.1) 
Phosphate  2 (2.1) 
Graft rejection (unspecified) 2 (2.1) 
Other 14 (14.6) 
 
* 96 out of 205 trials reported primary outcomes 
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 Records identified in Cochrane 
Kidney and Transplant Specialized 
Register (CKT)
N=1266
Records screened
N=1266
Records excluded after title and abstract review 
N=936
Reasons for exclusion
No CKD-related intervention 456
Not a randomized controlled trial 446
Excluded population 6
Duplicate 1
Full-text articles assessed for 
eligibility
N=355
Studies included
N=205
(219 trials; n=2174 participants*)
Records excluded after full-text review 
N=136
Reasons for exclusion
Excluded population 55
Not a randomized controlled trial 42
Non English article 25
Duplicate 11
No CKD-related intervention 3
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* Outcome measures shown are as named in the trials 
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* Outcome measures shown are as named in the trials 
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